A vs BIO stock comparison
Agilent Technologies vs. Bio-rad Laboratories · data as of November 13, 2026
Agilent Technologies (A) has a market value of about $49.0B, Bio-rad Laboratories (BIO) about $9.9B. Over their latest twelve months Agilent Technologies had revenue of $7.4B and Bio-rad Laboratories $2.6B.
On our five checks Agilent Technologies scores higher: 2.6 out of 5 (average) against 2.2 (weak).
By area, the stronger company is Bio-rad Laboratories on value; Bio-rad Laboratories on future growth; Agilent Technologies on track record; Agilent Technologies on shareholder returns.
Bio-rad Laboratories is cheaper on earnings (P/E 9.7 vs. 34.3), while Agilent Technologies grew revenue faster over five years (5.4% vs. 0.3% a year).
Agilent Technologies leads on 14 of the compared lines and Bio-rad Laboratories on 9.
Side by side
| A | BIO | |
|---|---|---|
| Size and price | ||
| Market cap | $49.0B | $9.9B |
| Share price | $173.96 | $366.36 |
| Score | ||
| Overall score (of 5) | 2.6 | 2.2 |
| Value | 0 | 2 |
| Future growth | 1 | 3 |
| Track record | 4 | 0 |
| Financial health | 3 | 3 |
| Shareholder returns | 5 | 3 |
| Valuation | ||
| P/E (TTM) | 34.3 | 9.7 |
| Forward P/E | 26.4 | 34.5 |
| Price / free cash flow | 38.7 | 29.9 |
| Price / sales | 6.7 | 3.8 |
| EV / EBITDA | 26.8 | 92.3 |
| PEG | 2.33 | — |
| DCF value vs. price | −42% | −62% |
| Business | ||
| Revenue | $7.4B | $2.6B |
| Net income | $1.4B | $1.0B |
| Free cash flow | $1.3B | $329M |
| Net margin | 19.5% | 39.5% |
| Gross margin (5-yr avg.) | 53.1% | 54.2% |
| ROIC (5-yr avg.) | 14.4% | 2.4% |
| Growth | ||
| Revenue growth (1 yr) | 6.7% | 0.7% |
| Revenue growth (5 yrs, per year) | 5.4% | 0.3% |
| EPS growth (5 yrs, per year) | 14.7% | -26.1% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$2.1B | $301M |
| Dividend yield | 0.59% | None |
| Shareholder yield | 1.5% | 3.0% |
| Analysts | ||
| Upside to average target | +5% | −3% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: A TTM to July 31, 2026, BIO TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Agilent Technologies or Bio-rad Laboratories?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Agilent Technologies scores 2.6 out of 5 and Bio-rad Laboratories 2.2; the table shows where each one is stronger.
Is Agilent Technologies cheaper than Bio-rad Laboratories?
On trailing earnings, Bio-rad Laboratories trades at a P/E of 9.7 and Agilent Technologies at 34.3, so Bio-rad Laboratories is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Agilent Technologies or Bio-rad Laboratories?
Over five years Agilent Technologies grew revenue about 5.4% a year and Bio-rad Laboratories about 0.3% a year.
Which pays a higher dividend?
Agilent Technologies yields 0.59% and Bio-rad Laboratories nothing (no dividend).
Full Agilent Technologies analysis → Full Bio-rad Laboratories analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.